Tech Company Financing Transactions
Janux Therapeutics Funding Round
Janux Therapeutics secured a $56 million Series A funding round on 3/4/2021. Backers included Avalon Ventures, Bregua and Correlation Ventures.
Transaction Overview
Company Name
Announced On
3/4/2021
Transaction Type
Venture Equity
Amount
$56,000,000
Round
Series A
Investors
Proceeds Purpose
The financing will be used to advance Janux's preclinical pipeline, including a TROP2-TRACTr and PSMA-TRACTr, with expected advancement of the Company's first candidate into the clinic in the first half of next year.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
11099 N. Torrey Pines Rd. 290
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Janux Therapeutics is developing safe, effective novel immunotherapies with the company's proprietary TRACTr technology. Janux's TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Campbell
Chief Financial Officer
Tighe Reardon
Vice President
Charles Winter
VP - Bus. Development
Andrew Meyer
VP - R & D
Tommy Diraimondo
Browse more venture capital transactions:
Prev: 3/4/2021: DTx Pharma venture capital transaction
Next: 3/4/2021: Papaya Global venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs